Key Points
High CO2 (hypercapnia) reduces macrophage activation and migration.
Our data implicate a novel CA2/[pH]i axis in CO2 sensing in cells.
Patients with lung disease are at risk of developing surgical complications.
Visual Abstract
Abstract
CO2, the primary gaseous product of respiration, is a major physiologic gas, the biology of which is poorly understood. Elevated CO2 is a feature of the microenvironment in multiple inflammatory diseases that suppresses immune cell activity. However, little is known about the CO2-sensing mechanisms and downstream pathways involved. We found that elevated CO2 correlates with reduced monocyte and macrophage migration in patients undergoing gastrointestinal surgery and that elevated CO2 reduces migration in vitro. Mechanistically, CO2 reduces autocrine inflammatory gene expression, thereby inhibiting macrophage activation in a manner dependent on decreased intracellular pH. Pharmacologic or genetic inhibition of carbonic anhydrases (CAs) uncouples a CO2-elicited intracellular pH response and attenuates CO2 sensitivity in immune cells. Conversely, CRISPR-driven upregulation of the isoenzyme CA2 confers CO2 sensitivity in nonimmune cells. Of interest, we found that patients with chronic lung diseases associated with elevated systemic CO2 (hypercapnia) display a greater risk of developing anastomotic leakage following gastrointestinal surgery, indicating impaired wound healing. Furthermore, low intraoperative pH levels in these patients correlate with reduced intestinal macrophage infiltration. In conclusion, CO2 is an immunomodulatory gas sensed by immune cells through a CA2-coupled change in intracellular pH.
This article is featured in Top Reads, p.
Footnotes
M.J.S. receives funding from the German Research Foundation (Grant STR 1570/1-1) and the Braun Foundation (Grant BBST-D-18-00018). M.S. received funding from the German Federal Ministry of Education and Research (Grant 031L0084) and from the German Research Foundation (Grant SCHN 947/4-2).
M.J.S., E.P.C., and C.T.T. designed the study. M.J.S., R.N., M.P.G., J.N., S.F., I.U., C.T., M.B.B., and D.P. conducted experiments. M.J.S., R.N., D.P., A.S.R., S.J.K., A.B., O.B., M.S., E.B., C.T., M.B.B., and E.P.C. conducted further data acquisition and analysis. M.J.S. and C.T.T. drafted the manuscript. M.J.S. prepared the figures. All authors critically revised and approved the final manuscript version.
The online version of this article contains supplemental material.
Abbreviations used in this article:
- ACTZ
- acetazolamide
- AL
- anastomotic leakage
- BCECF-AM
- 2′,7′-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxymethyl ester
- BM
- buffered medium
- BMDM
- bone marrow–derived macrophage
- CA
- carbonic anhydrase
- CM
- conditioned medium
- COPD
- chronic obstructive pulmonary disease
- HPF
- high-power field
- NTC
- nontargeting control
- OSA
- obstructive sleep apnea
- pCO2
- partial pressure of CO2
- pO2
- partial pressure of O2
- P/S
- penicillin/streptomycin
- RT-PCR
- real-time PCR
- siRNA
- small interfering RNA
- Received July 7, 2021.
- Accepted March 9, 2022.
- Copyright © 2022 by The American Association of Immunologists, Inc.
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$37.50
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.